Quality of life and symptoms of pain in patients with endometriomas compared to those with other endometriosis lesions: a cross-sectional study

Quality of life and symptoms of pain in patients with endometriomas compared to those with other endometriosis lesions: a cross-sectional study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Quality of life and symptoms of pain in patients with endometriomas compared to those with other endometriosis lesions: a cross-sectional study Fleur Serge Kanti, Valérie Allard, Sarah Maheux-Lacroix This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3734629/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 27 Jan, 2024 Read the published version in BMC Women's Health → Version 1 posted 13 You are reading this latest preprint version Abstract Background Endometriomas are genetically distinct from other endometriosis lesions and could be associated with a predisposition to excessive inflammation. However, differences in clinical presentation between types of endometriosis lesions remain understudied. This study aimed to investigate the quality of life and pain scores among patients with endometrioma compared to those with other types of endometriosis lesions. Methods A cross-sectional observational study was conducted between January 2020 and August 2023. Patients diagnosed with endometriosis completed the Endometriosis Health Profile 30 pain subscale questionnaire for their quality of life score and rated their endometriosis-associated pain symptoms using an 11-point numerical rating scale. Data were analyzed for comparison through multivariable linear regression models. Results A total of 248 patients were included and divided into endometrioma (81, 33%) and non-endometrioma (167, 67%) groups. The mean age of the patients was 37.1 ± 7.5 years old. Most participants were Canadian or North American (84%). One-third of the patients reported experiencing up to four concurrent pain symptoms. The most reported pain included deep dyspareunia (90%), chronic pelvic pain (84%) and lower back pain (81%). The mean quality of life score was 45.9 ± 25.9. We observed no difference in quality of life score between patients with and without endometriomas. Patients with endometriomas had lower mean scores for deep dyspareunia of 0.8 (95%CI, [0 to 1.5]; p = 0.049) and higher for superficial dyspareunia of 1.4 (95%CI, [0.2 to 2.6]; p = 0.028). Conclusion Among patients with endometriosis, the presence of endometriomas is not associated with a greater or lesser quality of life but difference in specific symptoms of dyspareunia. Endometriosis endometrioma quality of life Endometriosis Health Profile-30 pelvic pain infertility Figures Figure 1 Figure 2 Figure 3 Figure 4 Background Endometriosis is a common gynecological disorder that affects millions of women worldwide. It is characterized by the presence of endometrial tissue outside of the uterus. Endometrioma, which is the presence of an ovarian mass arising from ectopic endometrial tissue, is one of the most common manifestations of endometriosis [ 1 ]. The largest ever study on the genetics of endometriosis, involving DNA from more than 760,000 women, found endometrioma is genetically distinct from other types and indicated there may be a genetic predisposition to excessive inflammation in people with the condition [ 2 ]. However, differences in clinical presentation between types of endometriosis lesions remain understudied. Moreover, improving quality of life (QoL) is a primary goal of endometriosis treatment, and the European Society of Human Reproduction and Embryology has suggested studying how surgery impacts pain and QoL parameters in different subtypes of endometriosis [ 3 ]. This study aimed to investigate the QoL among patients with endometrioma compared to those with other types of endometriosis. Additionally, we sought out to examine pain scores in patients with endometrioma versus those with other types of endometriosis. Materials and methods Study design and participants This cross-sectional study was conducted as part of an ongoing prospective cohort focusing on patients seeking care at the gynecological outpatient clinic for initial or follow-up visits related to endometriosis. The cohort consists of participants from [center deleted to maintain the integrity of the review process]. Prior to enrolling participants, ethical approval ([reference number deleted to maintain the integrity of the review process]) was obtained from the research ethics committee of [center deleted to maintain the integrity of the review process]. The study lasted from January 2020 to August 2023. The target population consisted of premenopausal individuals who were invited to participate and underwent a comprehensive history and physical examination. To be included in the study, an individual had to be diagnosed with endometriosis, regardless of the method of diagnosis (ultrasound and/or magnetic resonance imaging in the last year, visualization of lesions during surgery or histological confirmation), be aged 18 or over, be willing to participate, and be able to read and understand French language and to complete a questionnaire. Participants were excluded if they did not report any symptom of pain (as the primary outcome was assessed using questions relating to pain) or their clinical evaluation did not allow for differentiation between endometrioma and other types of endometriosis, as imaging examinations and histopathology were not available at the time of the study. Study flow chart is shown in Fig. 1 . Data collection Participants provided written consent and self-completed a set of questionnaires either online or on paper before or after their outpatient clinic visit. The questionnaires were supplemented by findings from review of medical records. The main outcome measure was evaluated using the validated Endometriosis Health Profile-30 (EHP-30) questionnaire pain subscale consisting of the first 11 questions. The response options are “never,” “rarely,” “sometimes,” “often,” and “always.” The recall period is the last four weeks. This assessment examines how endometriosis-related pain affects QoL [ 4 ]. The QoL was assessed using the Canadian French version of the EHP-30 questionnaire [ 5 ]. The resulting score was then transformed into a scale ranging from 0 (indicating optimal QoL) to 100 (indicating worst QoL) [ 4 ]. The secondary outcomes included reports in the last three months of superficial dyspareunia, deep dyspareunia, dysmenorrhea, dyschezia, lower back pain and chronic pelvic pain. Participants rated these symptoms in intensity using an 11-point numerical rating scale (NRS) recommended for endometriosis research [ 6 ]. NRS scores ranged from 0 (indicating no pain) to 10 (indicating worst pain imaginable) [ 6 ]. Statistical analysis Our statistical analysis was completed using R software (version 4.3.1) [ 7 ]. The participants were divided into two groups based on the type of endometriosis: endometrioma and non-endometrioma groups. Continuous data were presented as mean ± standard deviation and/or median and range (minimum-maximum). Categorical data were reported as frequency (percentage). Comparison tests were performed between individuals with endometrioma vs. non-endometrioma using two-sample Wilcoxon-Mann-Whitney tests for continuous variables, and chi-square tests of independence or Fisher's exact tests for categorical variables when appropriate. Multivariable linear regression models were used to compare the primary (EHP-30 score for QoL) and secondary outcomes (NRS scores for symptoms of pain) between the endometrioma and non-endometrioma groups. The models were adjusted for age, body mass index, ethnicity, age of menarche, parity, education level, employment status, marital status, annual income, and hormone use in the last three months. Sub-group analyses were performed to determine whether differences in either QoL score or NRS pain scores (when comparing endometrioma group to non-endometrioma group) were associated with potential modification factors. To do so, an interaction term between each factor and variable of interest was added to the models. The factors were the diagnosis method (imaging modalities/histology), concurrent pain symptoms (1–4/5–6), comorbid infertility (yes/no), presence of adenomyosis (yes/no), presence of fibroma (yes/no), moderate symptoms of depression (yes/no), moderate symptoms of anxiety (yes/no), pain catastrophizing (yes/no) and central component of pain (yes/no). To aid in clinical interpretation, analyses with cutoffs were conducted using multivariable logistic regression models. The EHP-30 score was categorized as impaired (score ≥ 75th centile of EHP-30 score population distribution) or best (score < 75th centile of EHP-30 score population distribution) quality of life. The pain NRS scores were categorized as severe (7–10) or mild-moderate (1–6) intensity. We estimated the point estimates, i.e., linear regression coefficients (β) as mean differences for either QoL or pain symptoms scores, and odds ratios (OR) as ratios of the odds of probability for having either impaired QoL or each severe pain symptom. The estimates were supplemented by their confidence intervals (CI) of 95%. Statistical significance was established for values of p < 0.05 for all analyses. A p < 0.05 for the interaction term in sub-group analyses indicated that there was a statistically significant difference in effect of the variable of interest on the outcome regarding the whole factor. No sample size calculation was conducted. Participants were included over a complete period to obtain a representative sample of patients with frequent hospital visits. We therefore performed a post hoc power calculation to assess the statistical power of our main analyses [ 8 ]. This allowed us to determine that the study was adequately powered to detect minimal clinical differences relevant to patients or healthcare providers [ 9 – 11 ] (Figure S1 ). Results Characteristics of the study population and outcomes distributions Out of the 335 individuals who were screened, a total of 248 participants (74%) met the criteria for inclusion in our study and were divided into the endometrioma group (81/248; 33%) and non-endometrioma group (167/248; 67%) (Fig. 1 ). The mean age of the patients was 37.1 ± 7.5 years old, with an average body mass index of 26.6 ± 5.7 Kg/m 2 . Most participants were Canadian or North American, accounting for 84% of the sample population. A large proportion of the participants (78%) had their first menstrual period at or before the age of 13, while more than half (54%) was nulliparous. One-third of the patients reported experiencing up to four pain symptoms simultaneously (34%). The non-endometrioma group showed a longer duration of pain symptoms (p = 0.047), lower prevalence of presentation of up to four concurrent pain symptoms (p = 0.031) and higher prevalence of adenomyosis (p = 0.02). No statistically significant difference between endometrioma and non-endometrioma patients emerged across other variables (Table 1 ). On average, the QoL score was 45.9 ± 25.9. The most reported pain symptoms included deep dyspareunia (90%), chronic pelvic pain (84%) and lower back pain (81%). In cases of severe symptoms (pain intensity of 7 or above), the most common symptoms reported were dysmenorrhea (66%), deep dyspareunia (58%), and chronic pelvic pain (50%) (Table 2 ). Table 1 Main characteristics of the study population Variables Endometriosis 1 Total (N = 248) p-value 2 Endometrioma (n = 81) Non endometrioma (n = 167) Age (years) 37.0 ± 7.1 37.1 ± 7.8 37.1 ± 7.5 0.86 Body mass index (Kg/m 2 ) 26.4 ± 5.6 26.7 ± 5.8 26.6 ± 5.7 0.83 Canadian or North American 69 (85.2%) 139 (83.2%) 208 (83.9%) 0.70 University level 40 (50.0%) 62 (37.1%) 102 (41.3%) 0.15 Working currently 71 (87.7%) 133 (79.6%) 204 (82.3%) 0.12 In a relationship/married/spouse 66 (81.5%) 143 (85.6%) 209 (84.3%) 0.40 Menarche ≤ 13 years old 60 (74.1%) 133 (79.6%) 193 (77.8%) 0.32 Nulliparous 46 (56.8%) 88 (52.7%) 134 (54.0%) 0.54 Years since onset of pain symptoms 9 (3–18) 12 (5–22) 11 (5–20) 0.047 Smoking 5 (17.9%) 15 (29.4%) 20 (25.3%) 0.26 Hormonal suppression in the last 3 months 41 (64.1%) 90 (60.0%) 131 (61.2%) 0.58 Comorbid infertility 13 (16.0%) 20 (12.0%) 33 (13.3%) 0.38 Reporting 1–4 concurrent pain symptoms 31 (44.3%) 40 (29.2%) 71 (34.3%) 0.031 Adenomyosis 2 (4.9%) 12 (21.8%) 14 (14.6%) 0.020 Fibroma 12 (57.1%) 38 (79.2%) 50 (72.5%) 0.060 Pain catastrophizing (PCS ≥ 27) 19 (23.5%) 48 (28.7%) 67 (27.0%) 0.38 Moderate anxiety (GAD-7 ≥ 10) 6 (23.1%) 14 (23.0%) 20 (23.0%) 0.99 Moderate depression (PHQ-9 ≥ 10) 9 (34.6%) 21 (34.4%) 30 (34.5%) 0.99 Central component of pain (CSI ≥ 40) 5 (11.1%) 15 (17.9%) 20 (15.5%) 0.31 Abbreviations: PCS, Pain Catastrophizing Scale; GAD-7, Generalized Anxiety Disorder; PHQ-9, Patient Health Questionnaire-9; CSI, Central Sensitization Inventory. 1 Values are given in mean ± standard deviation, median (interquartile range), and frequency (percentage). 2 Wilcoxon rank sum test for continuous variables; and Pearson’s Chi-squared test or Fisher’s exact test otherwise. Table 2 Distribution of the outcomes Variables 1 Endometriosis 2 Total (N = 248) Endometrioma (n = 81) Non endometrioma (n = 167) Quality of life EHP-30 score 42.4 ± 25.2 47.6 ± 26.2 45.9 ± 25.9 Impaired (EHP-30 score ≥ 66) 21 (25.9%) 48 (28.7%) 69 (27.8%) Not available 0 0 0 Superficial dyspareunia Have reported 37 (49.3%) 98 (64.1%) 135 (59.2%) Intensity 5.0 ± 2.6 4.1 ± 2.6 4.3 ± 2.6 Severe (intensity ≥ 7) 10 (27.0%) 20 (20.4%) 30 (22.2%) Not available 6 14 20 Deep dyspareunia Have reported 68 (89.5%) 138 (90.2%) 206 (90.0%) Intensity 6.0 ± 2.5 6.7 ± 2.2 6.5 ± 2.3 Severe (intensity ≥ 7) 35 (51.5%) 85 (61.6%) 120 (58.3%) Not available 5 14 19 Dysmenorrhea Have reported 57 (75.0%) 124 (81.6%) 181 (79.4%) Intensity 6.6 ± 2.7 7.4 ± 2.3 7.1 ± 2.4 Severe (intensity ≥ 7) 36 (63.2%) 83 (66.9%) 119 (65.7%) Not available 5 15 20 Dyschezia Have reported 50 (61.7%) 135 (81.8%) 185 (75.2%) Intensity 4.9 ± 2.4 5.0 ± 2.5 5.0 ± 2.4 Severe (intensity ≥ 7) 14 (28.0%) 39 (28.9%) 53 (28.6%) Not available 0 2 2 Lower back pain Have reported 64 (79.0%) 137 (82.0%) 201 (81.0%) Intensity 5.6 ± 2.3 6.4 ± 2.1 6.1 ± 2.2 Severe (intensity ≥ 7) 24 (37.5%) 65 (47.4%) 89 (44.3%) Not available 0 0 0 Chronic pelvic pain Have reported 64 (79.0%) 143 (85.6%) 207 (83.5%) Intensity 6.3 ± 2.0 6.6 ± 2.3 6.5 ± 2.2 Severe (intensity ≥ 7) 27 (42.2%) 76 (53.1%) 103 (49.8%) Not available 0 0 0 Abbreviation: EHP-30, Endometriosis Health Profile-30. 1 Pain intensity is the numerical rating scale score ranging from 0 (indicating no pain) to 10 (indicating worst pain imaginable); the EHP-30 score ranges from 0 (indicating optimal quality of life) to 100 (indicating worst quality of life); each “Not available” row displays the number of missing values; each “Have reported” row denotes the number of cases that reported the corresponding symptom of pain. 2 Values are given in mean ± standard deviation and frequency (percentage). Association between QoL and endometriomas The unadjusted and adjusted analyses for QoL scores indicated no difference between patients with and without endometriomas (mean difference of -4.9 (95%CI, [-12.7 to 2.9]; p = 0.214) and − 2.9 (95%CI, [-10.5 to 4.8]; p = 0.458) respectively) (Fig. 2 ). No statistically significant difference in QoL score between participants with endometriomas and those without emerged across the modifying factors. When considering only participants reporting moderate symptoms of depression, there was significantly lower mean QoL score at 29.3 (95%CI, [3.9 to 54.8]) for patients with endometriomas compared to those without (Fig. 3 ). Association between pain scores and endometriomas Participants with endometriomas versus those without endometriomas exhibited significantly higher mean scores for superficial dyspareunia of 1.4 (95%CI, [0.2 to 2.6]; p = 0.028), and significantly lower mean scores for deep dyspareunia of 0.8 (95%CI, [0 to 1.5]; p = 0.049) in adjusted analyses. For other pain symptoms (dysmenorrhea, dyschezia, lower back pain, chronic pelvic pain), there was no statistically significant differences in mean differences (Fig. 2 ). Comorbid infertility (p = 0.049) was found to be a factor that influenced the results for superficial dyspareunia, with an average difference in scores of 4.6 (95%CI, [1.2 to 8.1]) if infertility vs 0.9 (95%CI, [-0.3 to 2.2]) otherwise (Figure S2). The central component of pain (p = 0.041) emerged as a factor that modified the potential average difference in scores for chronic pelvic pain (2.54; 95%CI, [-0.4 to 5.5] if central component of pain vs -0.7; 95%CI, [-1.8 to 0.3] otherwise (Figure S3). Considering solely the levels of modifying factors, statistically significant mean score differences were found between participants with endometriomas and those without (i.e., 95% confidence intervals did not include zero). These differences were observed in individuals reporting up to four concurrent symptoms of pain, comorbid infertility, moderate symptoms of anxiety and pain catastrophizing for superficial dyspareunia (Figure S2), absence of a central component in pain experience and no pain catastrophizing for deep dyspareunia (Figure S4), and presence of a central component in pain experience and no pain catastrophizing for lower back pain (Figure S5). No such differences were identified for chronic pelvic pain (Figure S3), dysmenorrhea (Figure S6), dyschezia (Figure S7). Odd radios of impaired QoL and severe pain symptoms The OR for impaired QoL (endometrioma vs non-endometrioma) was 1.05 (95%CI, [0.5 to 2.19]; p = 0.89). For symptoms of pain, the OR ranged from 0.52 (95%CI, [0.25 to 1.08]; p = 0.08) for severe deep dyspareunia to 2.11 (95%CI, [0.60 to 7.43]; p = 0.24). Endometrioma was not associated with impaired QoL or any severe symptoms of pain, but the confidence intervals in adjusted analyses indicated that the data were compatible with an OR both greater than and less than 1 (Fig. 4 ). Discussion In this study, we found no difference in quality of life between patients with and without endometriomas. In terms of pain scores, there were differences in deep and superficial dyspareunia. The study echoes research aiming to better quantify and compare endometriosis-associated pain experienced by different women or identify different subpopulations of women with endometriosis. Since no current cure exists for endometriosis, this research supports the development of targeted treatments appropriate to a group with similar clinical experience or to a given subpopulation's underlying biological differences [ 2 , 12 ]. The study focused on the quality of life of patients with endometriosis who have different types of lesions. It specifically looks at how endometriosis, as a chronic inflammatory illness, affects their quality of life rather than just considering the presence or absence of pain symptoms. Indeed, the study only involved people who had experienced at least one symptom of pain. These findings add to the limited evidence in terms of the variation in pain and quality of life across endometriosis types. The findings echo earlier research indicating that endometriosis, regardless of type, significantly impacts patients’ quality of life and pain experiences. Patients with endometriosis seem to have an overall impaired quality of life compared to patients from the general population, including daily tasks, marital/sexual relationships, social life, and employment, as well as physical and psychological aspects of life [ 13 – 20 ]. In contrast to these previous studies, it should be emphasized that we focused on evaluating quality of life specifically about the experience of pain. While patients with endometriomas indicated significantly higher scores for superficial dyspareunia, lower scores were noted for deep dyspareunia. This finding supports that the pain experience in endometriosis may vary by symptom and endometriosis subtype [ 21 ] since pain may also be due to the anatomical distortion that endometriomas create in the pelvis [ 22 ]. Endometriomas often co-occur with deep endometriosis [ 1 ]. In this study, the endometrioma group included all cases of endometrioma, regardless of other subtypes. Our study highlights the complex impact of endometriosis and co-occurring conditions (like depression) on quality of life, underscoring the importance of personalized care strategies, including medical, psychological, and non-medical interventions such as physical therapy and lifestyle changes. It also emphasizes the need for the development of targeted medical and surgical treatments to improve patient outcomes. Variations in the perception, nature, and intensity of pain among individuals can account for the differences observed in the results. Additionally, there may be associations between different pain symptoms that contribute to these variations. The finding that associated conditions such as depression could significantly affect quality of life in endometrioma patients compared to non-endometrioma suggests that healthcare providers should consider diagnostic strategies to identify such conditions and involve them in the overall management approach. Other studies will be required to understand which factors explained differences in quality of life among patients with endometriosis. Strengths of this study included a substantial sample size for main analyses (with sufficient power to detect clinically relevant mean difference), the use of a validated measure for quality of life in the endometriosis population (EHP-30) and the use of appropriate and validated statistical methods to analyze the data. We considered a wide range of modifying factors (such as adenomyosis, comorbid infertility, and psychological factors), which provides a more comprehensive view of factors influencing quality of life and pain in endometriosis patients. The focus on comparing quality of life and pain experiences between endometrioma and other types of endometriosis (comparisons among patients with endometriosis) is a distinct feature of this study, which contributes unique findings to the research field. However, the study was limited by its cross-sectional design, which prevents the ability to establish cause-effect relationships between different types of endometrioses and quality of life or pain experiences. The participants were recruited from a specific clinical setting, which might limit the representativeness of the findings to all patients with endometriosis. Future research could benefit from a longitudinal design to determine changes in quality of life and pain scores over time, helping to explore in more depth the relationships between different types of endometrioses, quality of life, specific pain experiences, and other influencing factors. This could lead to more effective approaches to improve the quality of life of endometriosis patients. Further exploration of personalized treatment plans based on the type of endometriosis and the patient's symptoms and assessments of quality of life could be valuable. Conclusion Among patients with endometriosis, the presence of endometriomas was not associated with a greater or lesser quality of life but difference in specific symptoms of dyspareunia. Further studies will be required to understand which factors explained differences in quality of life among patients with endometriosis. Abbreviations CI: Confidence interval EHP-30: Endometriosis Health Profile-30 NRS: numerical rating scale OR: odds ratios QoL: quality of life Declarations Ethics approval and consent to participate Ethical approval (#2020-4972) was obtained from the research ethics committee of Centre Hospitalier Universitaire de Québec-Université Laval. Written informed consent was obtained from each participant before participating in the study. Consent for publication Not applicable. Availability of data and materials The datasets generated and/or analyzed during the current study are not publicly available due to privacy/ethical restrictions but are available from the corresponding author (FSK) on reasonable request and with permission of SML. Competing interests The authors declare that they have no conflicts of interest and nothing to disclose. Funding This research project was funded by the Canadian Institutes of Health Research. S.M.-L. is the recipient of a Career Award from the Fonds de Recherche Québec-Santé. The sponsors had no role in the study design; collection, analysis, and interpretation of data; writing of the report; or the decision to submit the report for publication. Authors' contributions Study Conception and Design: FSK, VA, SML Data Collection: FSK, VA, SML Statistical Analysis: FSK Data Analysis and Interpretation of Results: FSK, VA, SML Writing - Original Draft: FSK Writing - Review and Editing: FSK, VA, SML Supervision: SML Acknowledgements Not applicable. Authors' information FSK, MD, MPH: Doctoral student in epidemiology (Reproduction, mother and youth health). VA, MSc: Nurse clinician and research professional (Reproduction, mother and youth health). SML, MD, PhD: Gynecologist, clinician-researcher and assistant professor (Reproduction, mother and youth health). References C. Allaire, M. A. Bedaiwy, and P. J. Yong, “Diagnosis and management of endometriosis,” CMAJ , vol. 195, no. 10, pp. E363–E371, Mar. 2023, doi: 10.1503/cmaj.220637. N. Rahmioglu et al. , “The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions,” Nat. Genet. , vol. 55, no. 3, Art. no. 3, Mar. 2023, doi: 10.1038/s41588-023-01323-z. C. M. Becker et al. , “ESHRE guideline: endometriosis,” Hum. Reprod. Open , vol. 2022, no. 2, p. hoac009, Feb. 2022, doi: 10.1093/hropen/hoac009. G. Jones, S. Kennedy, A. Barnard, J. Wong, and C. Jenkinson, “Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30,” Obstet. Gynecol. , vol. 98, no. 2, pp. 258–264, Aug. 2001, doi: 10.1016/S0029-7844(01)01433-8. E. Dimentberg, C. Cardaillac, E. Richard, A.-S. Plante, and S. Maheux-Lacroix, “Translation and Cultural Validation of the WERF EPHect Endometriosis Patient Questionnaire into Canadian French,” J. Obstet. Gynaecol. Can. JOGC J. Obstet. Gynecol. Can. JOGC , vol. 43, no. 7, pp. 817–821, Jul. 2021, doi: 10.1016/j.jogc.2021.03.019. K. Vincent, S. Kennedy, and P. Stratton, “Pain scoring in endometriosis: entry criteria and outcome measures for clinical trials. Report from the Art and Science of Endometriosis meeting,” Fertil. Steril. , vol. 93, no. 1, pp. 62–67, Jan. 2010, doi: 10.1016/j.fertnstert.2008.09.056. R Core Team, “R: A language and environment for statistical computing.” R Foundation for Statistical Computing, Vienna, Austria, 2023. [Online]. Available: https://www.R-project.org/ J. A. Hanley and E. E. M. Moodie, “Sample Size, Precision and Power Calculations: A Unified Approach,” J. Biom. Biostat. , vol. 2, no. 124, pp. 1–9, 2011, doi: http://dx.doi.org/10.4172/2155-6180.1000124. T. J. M. van de Burgt, K. B. Kluivers, and J. C. M. Hendriks, “Responsiveness of the Dutch Endometriosis Health Profile-30 (EHP-30) questionnaire,” Eur. J. Obstet. Gynecol. Reprod. Biol. , vol. 168, no. 1, pp. 92–94, May 2013, doi: 10.1016/j.ejogrb.2012.12.037. R. Pokrzywinski, A. M. Soliman, J. Chen, M. C. Snabes, H. S. Taylor, and K. S. Coyne, “Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials,” J. Womens Health , vol. 29, no. 2, pp. 253–261, Feb. 2020, doi: 10.1089/jwh.2019.7788. R. M. Pokrzywinski, A. M. Soliman, M. C. Snabes, J. Chen, H. S. Taylor, and K. S. Coyne, “Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis,” Fertil. Steril. , vol. 115, no. 2, pp. 423–430, Feb. 2021, doi: 10.1016/j.fertnstert.2020.07.013. A. Muraoka et al. , “Fusobacterium infection facilitates the development of endometriosis through the phenotypic transition of endometrial fibroblasts,” Sci. Transl. Med. , vol. 15, no. 700, p. eadd1531, Jun. 2023, doi: 10.1126/scitranslmed.add1531. G. Jones, C. Jenkinson, and S. Kennedy, “The impact of endometriosis upon quality of life: a qualitative analysis,” J. Psychosom. Obstet. Gynecol. , vol. 25, no. 2, pp. 123–133, Jan. 2004, doi: 10.1080/01674820400002279. K. E. Nnoaham et al. , “Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries,” Fertil. Steril. , vol. 96, no. 2, pp. 366-373.e8, Aug. 2011, doi: 10.1016/j.fertnstert.2011.05.090. M. Moradi, M. Parker, A. Sneddon, V. Lopez, and D. Ellwood, “Impact of endometriosis on women’s lives: a qualitative study,” BMC Womens Health , vol. 14, no. 1, p. 123, Oct. 2014, doi: 10.1186/1472-6874-14-123. K. Chaman-Ara, M. A. Bahrami, M. Moosazadeh, and E. Bahrami, “Quality of life in women with endometriosis: a systematic review and meta-analysis,” World Cancer Res. J. Accept. Artic. , 2017. A. M. Soliman, K. S. Coyne, K. S. Gries, J. Castelli-Haley, M. C. Snabes, and E. S. Surrey, “The Effect of Endometriosis Symptoms on Absenteeism and Presenteeism in the Workplace and at Home,” J. Manag. Care Spec. Pharm. , vol. 23, no. 7, pp. 745–754, Jul. 2017, doi: 10.18553/jmcp.2017.23.7.745. L. Della Corte et al. , “The Burden of Endometriosis on Women’s Lifespan: A Narrative Overview on Quality of Life and Psychosocial Wellbeing,” Int. J. Environ. Res. Public. Health , vol. 17, no. 13, p. 4683, Jul. 2020, doi: 10.3390/ijerph17134683. D. Warzecha, I. Szymusik, M. Wielgos, and B. Pietrzak, “The Impact of Endometriosis on the Quality of Life and the Incidence of Depression—A Cohort Study,” Int. J. Environ. Res. Public. Health , vol. 17, no. 10, p. 3641, May 2020, doi: 10.3390/ijerph17103641. M. Kalfas, C. Chisari, and S. Windgassen, “Psychosocial factors associated with pain and health‐related quality of life in Endometriosis: A systematic review,” Eur. J. Pain Lond. Engl. , vol. 26, no. 9, pp. 1827–1848, Oct. 2022, doi: 10.1002/ejp.2006. F. Facchin et al. , “Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference,” J. Psychosom. Obstet. Gynecol. , vol. 36, no. 4, pp. 135–141, Oct. 2015, doi: 10.3109/0167482X.2015.1074173. A. V. de A. Florentino, A. M. G. Pereira, J. A. Martins, R. G. C. Lopes, and R. M. Arruda, “Quality of Life Assessment by the Endometriosis Health Profile (EHP-30) Questionnaire Prior to Treatment for Ovarian Endometriosis in Brazilian Women,” Rev. Bras. Ginecol. E Obstetrícia RBGO Gynecol. Obstet. , vol. 41, no. 09, pp. 548–554, Sep. 2019, doi: 10.1055/s-0039-1693057. Additional Declarations No competing interests reported. Supplementary Files Supplementaryfile.docx Cite Share Download PDF Status: Published Journal Publication published 27 Jan, 2024 Read the published version in BMC Women's Health → Version 1 posted Editorial decision: Revision requested 20 Dec, 2023 Reviews received at journal 19 Dec, 2023 Reviewers agreed at journal 18 Dec, 2023 Reviews received at journal 18 Dec, 2023 Reviewers agreed at journal 13 Dec, 2023 Reviews received at journal 12 Dec, 2023 Reviewers agreed at journal 11 Dec, 2023 Reviewers agreed at journal 11 Dec, 2023 Reviewers invited by journal 11 Dec, 2023 Editor assigned by journal 11 Dec, 2023 Editor invited by journal 10 Dec, 2023 Submission checks completed at journal 10 Dec, 2023 First submitted to journal 10 Dec, 2023 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3734629","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":258388642,"identity":"1a1d829f-4384-4b2f-b8d9-befbd0bbe6c8","order_by":0,"name":"Fleur Serge Kanti","email":"data:image/png;base64,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","orcid":"","institution":"Centre hospitalier universitaire de Québec - Université Laval","correspondingAuthor":true,"prefix":"","firstName":"Fleur","middleName":"Serge","lastName":"Kanti","suffix":""},{"id":258388643,"identity":"eb60b739-6788-447b-b116-2a3b6c654e17","order_by":1,"name":"Valérie Allard","email":"","orcid":"","institution":"Centre hospitalier universitaire de Québec - Université Laval","correspondingAuthor":false,"prefix":"","firstName":"Valérie","middleName":"","lastName":"Allard","suffix":""},{"id":258388644,"identity":"3d7982cf-91b4-4455-8d3a-e8914af78cdb","order_by":2,"name":"Sarah Maheux-Lacroix","email":"","orcid":"","institution":"Centre hospitalier universitaire de Québec - Université Laval","correspondingAuthor":false,"prefix":"","firstName":"Sarah","middleName":"","lastName":"Maheux-Lacroix","suffix":""}],"badges":[],"createdAt":"2023-12-10 15:14:12","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3734629/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3734629/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12905-024-02919-1","type":"published","date":"2024-01-27T15:18:40+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":48155154,"identity":"9db3dcfa-a81d-49ae-a6d2-907ee4775d93","added_by":"auto","created_at":"2023-12-13 20:12:25","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":36563,"visible":true,"origin":"","legend":"\u003cp\u003eStudy population flow chart.\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-3734629/v1/f1c9678a26e273415b6dce94.png"},{"id":48156754,"identity":"b97b9032-07a3-4f51-bd57-a49e4f932c5f","added_by":"auto","created_at":"2023-12-13 20:20:26","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":146608,"visible":true,"origin":"","legend":"\u003cp\u003eQuality of life and pain symptoms scores of patients with different endometriosis lesions.\u003c/p\u003e\n\u003cp\u003eAbbreviation: CI, Confidence interval.\u003c/p\u003e\n\u003cp\u003eNotes:\u003c/p\u003e\n\u003cp\u003eNanalysis denotes the number of individuals available for analysis whilst Ncohort denotes the total number of people enrolled in the cohort. The differences between adjusted and non-adjusted models are observations deleted due to missingness.\u003c/p\u003e\n\u003cp\u003eβ linear regression coefficients mean differences in quality of life or pain symptoms scores.\u003c/p\u003e\n\u003cp\u003eThe vertical black dashed line represents the null value (0) of the mean difference, indicating a mean difference significantly different from 0 when its confidence interval does not include it (equivalent to p \u0026lt; 0.05).\u003c/p\u003e\n\u003cp\u003eThe mean differences of quality-of-life score or pain symptoms intensity are indicated by the blue squares (point estimates values) with their 95% confidence interval delimited by the black horizontal solid (adjusted model) or dashed (unadjusted model) lines.\u003c/p\u003e\n\u003cp\u003eThe models are adjusted for age, body mass index (Kg/m2), ethnicity, age of menarche, parity, education level, employment status, marital status, annual income, and hormone use in the last three months.\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-3734629/v1/8c8995d88c4f23de02baf0b7.png"},{"id":48155155,"identity":"071cb29b-6c86-46ab-8348-52e0f497d740","added_by":"auto","created_at":"2023-12-13 20:12:26","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":171614,"visible":true,"origin":"","legend":"\u003cp\u003eSub-group analyses for mean difference of Endometriosis Health Profile-30 score.\u003c/p\u003e\n\u003cp\u003eAbbreviation: CI, Confidence interval.\u003c/p\u003e\n\u003cp\u003eNotes:\u003c/p\u003e\n\u003cp\u003eβ denotes linear regression coefficient (mean difference in quality of life).\u003c/p\u003e\n\u003cp\u003eThe modification factors are the diagnosis method (imaging modalities/histology), concurrent pain symptoms (1-4/5-6), comorbid infertility (yes/no), presence of adenomyosis (yes/no), presence of fibroma (yes/no), moderate depression symptoms (yes/no), moderate anxiety symptoms (yes/no), pain catastrophizing (yes/no) and central component of pain (yes/no).\u003c/p\u003e\n\u003cp\u003eEach P-value is for each factor in its modification or not of the association between Endometriosis Health Profile-30 (EHP-30) score and endometrioma (modification factor if P\u0026lt;0.05; not otherwise), also allowing to compare the mean difference between modification factor levels. For each level of each factor, the mean difference of EHP-30 scores between patients with endometrioma compared to those with other types of endometriosis is indicated by the blue square (point estimate value) with their 95% confidence interval delimited by the black horizontal solid line.\u003c/p\u003e\n\u003cp\u003eThe vertical black dashed line represents the null value (0) of the mean difference, indicating a mean difference significantly different from 0 when its confidence interval does not include it (equivalent to p \u0026lt; 0.05; not displayed here).\u003c/p\u003e\n\u003cp\u003eThe models are adjusted for age, body mass index (Kg/m\u003csup\u003e2\u003c/sup\u003e), ethnicity, age of menarche, parity, education level, employment status, marital status, annual income, hormone use in the last three months, and each modification factor using an interaction term with the endometriosis type variable.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-3734629/v1/1752cba38263b32fb0e15f90.png"},{"id":48155157,"identity":"6bd0cb59-3a9c-4786-97d0-ead0ecf99a22","added_by":"auto","created_at":"2023-12-13 20:12:26","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":160539,"visible":true,"origin":"","legend":"\u003cp\u003eImpaired quality of life and severe pain symptoms of patients with different endometriosis lesions.\u003c/p\u003e\n\u003cp\u003eAbbreviations: OR, odd radios; CI, Confidence interval.\u003c/p\u003e\n\u003cp\u003eNotes:\u003c/p\u003e\n\u003cp\u003eOR denotes ratios of the odds of probability for having either impaired quality of life or each severe pain symptom.\u003c/p\u003e\n\u003cp\u003eN\u003csub\u003eoutcomes\u003c/sub\u003e denotes the number of patients or individuals which had the outcome in a particular group whilst N\u003csub\u003egroup\u003c/sub\u003e denotes the total number of people in that group. “E\u003csub\u003e1\u003c/sub\u003e” denotes endometrioma group, and “E\u003csub\u003e0\u003c/sub\u003e”, non-endometrioma group.\u003c/p\u003e\n\u003cp\u003eThe quality of life is evaluated using the validated Endometriosis Health Profile-30 (EHP-30) questionnaire pain subscale. The EHP-30 score is categorized as impaired (score ≥ 75th centile of EHP-30 score population distribution) or best (score \u0026lt; 75th centile of EHP-30 score population distribution) quality of life.\u003c/p\u003e\n\u003cp\u003ePain symptoms are evaluated using an 11-point numerical rating scale (NRS). Scores ranged from 0 (indicating no pain) to 10 (indicating worst pain imaginable). The pain NRS scores are categorized as mild-moderate (1-6) or severe (7-10) intensity of pain symptoms.\u003c/p\u003e\n\u003cp\u003eThe vertical black dashed line represents the null value of the odd ratios (1), indicating an odd ratio significantly different from 1 when its confidence interval does not include it (equivalent to p \u0026lt; 0.05).\u003c/p\u003e\n\u003cp\u003eThe odds ratios of impaired quality of life EHP-30 scores, or severe pain symptoms are indicated by the blue squares (point estimates values) with their 95% confidence interval delimited by the black horizontal solid lines.\u003c/p\u003e\n\u003cp\u003eThe models are adjusted for age, body mass index (Kg/m\u003csup\u003e2\u003c/sup\u003e), ethnicity, age of menarche, parity, education level, employment status, marital status, annual income, and hormone use in the last three months.\u003c/p\u003e","description":"","filename":"Figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-3734629/v1/3a20cb7a325282a3c891e5ef.png"},{"id":50314328,"identity":"62dd414a-aeb4-43f5-8dd6-b3e62468f084","added_by":"auto","created_at":"2024-01-29 15:30:15","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":901741,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3734629/v1/30ac8c3f-d3d7-4892-ae2f-c3090afcad67.pdf"},{"id":48155159,"identity":"f18b51f0-fdb0-4ac1-bbed-02ed0d36cbe8","added_by":"auto","created_at":"2023-12-13 20:12:27","extension":"docx","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":9443058,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementaryfile.docx","url":"https://assets-eu.researchsquare.com/files/rs-3734629/v1/9a10d484a4ab4ec55e65cfe4.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Quality of life and symptoms of pain in patients with endometriomas compared to those with other endometriosis lesions: a cross-sectional study","fulltext":[{"header":"Background","content":"\u003cp\u003eEndometriosis is a common gynecological disorder that affects millions of women worldwide. It is characterized by the presence of endometrial tissue outside of the uterus. Endometrioma, which is the presence of an ovarian mass arising from ectopic endometrial tissue, is one of the most common manifestations of endometriosis [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. The largest ever study on the genetics of endometriosis, involving DNA from more than 760,000 women, found endometrioma is genetically distinct from other types and indicated there may be a genetic predisposition to excessive inflammation in people with the condition [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. However, differences in clinical presentation between types of endometriosis lesions remain understudied. Moreover, improving quality of life (QoL) is a primary goal of endometriosis treatment, and the European Society of Human Reproduction and Embryology has suggested studying how surgery impacts pain and QoL parameters in different subtypes of endometriosis [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThis study aimed to investigate the QoL among patients with endometrioma compared to those with other types of endometriosis. Additionally, we sought out to examine pain scores in patients with endometrioma versus those with other types of endometriosis.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy design and participants\u003c/h2\u003e \u003cp\u003eThis cross-sectional study was conducted as part of an ongoing prospective cohort focusing on patients seeking care at the gynecological outpatient clinic for initial or follow-up visits related to endometriosis. The cohort consists of participants from [center deleted to maintain the integrity of the review process]. Prior to enrolling participants, ethical approval ([reference number deleted to maintain the integrity of the review process]) was obtained from the research ethics committee of [center deleted to maintain the integrity of the review process].\u003c/p\u003e \u003cp\u003eThe study lasted from January 2020 to August 2023. The target population consisted of premenopausal individuals who were invited to participate and underwent a comprehensive history and physical examination. To be included in the study, an individual had to be diagnosed with endometriosis, regardless of the method of diagnosis (ultrasound and/or magnetic resonance imaging in the last year, visualization of lesions during surgery or histological confirmation), be aged 18 or over, be willing to participate, and be able to read and understand French language and to complete a questionnaire. Participants were excluded if they did not report any symptom of pain (as the primary outcome was assessed using questions relating to pain) or their clinical evaluation did not allow for differentiation between endometrioma and other types of endometriosis, as imaging examinations and histopathology were not available at the time of the study. Study flow chart is shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eData collection\u003c/h2\u003e \u003cp\u003e Participants provided written consent and self-completed a set of questionnaires either online or on paper before or after their outpatient clinic visit. The questionnaires were supplemented by findings from review of medical records.\u003c/p\u003e \u003cp\u003eThe main outcome measure was evaluated using the validated Endometriosis Health Profile-30 (EHP-30) questionnaire pain subscale consisting of the first 11 questions. The response options are \u0026ldquo;never,\u0026rdquo; \u0026ldquo;rarely,\u0026rdquo; \u0026ldquo;sometimes,\u0026rdquo; \u0026ldquo;often,\u0026rdquo; and \u0026ldquo;always.\u0026rdquo; The recall period is the last four weeks. This assessment examines how endometriosis-related pain affects QoL [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. The QoL was assessed using the Canadian French version of the EHP-30 questionnaire [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. The resulting score was then transformed into a scale ranging from 0 (indicating optimal QoL) to 100 (indicating worst QoL) [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. The secondary outcomes included reports in the last three months of superficial dyspareunia, deep dyspareunia, dysmenorrhea, dyschezia, lower back pain and chronic pelvic pain. Participants rated these symptoms in intensity using an 11-point numerical rating scale (NRS) recommended for endometriosis research [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. NRS scores ranged from 0 (indicating no pain) to 10 (indicating worst pain imaginable) [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eOur statistical analysis was completed using R software (version 4.3.1) [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. The participants were divided into two groups based on the type of endometriosis: endometrioma and non-endometrioma groups. Continuous data were presented as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation and/or median and range (minimum-maximum). Categorical data were reported as frequency (percentage). Comparison tests were performed between individuals with endometrioma vs. non-endometrioma using two-sample Wilcoxon-Mann-Whitney tests for continuous variables, and chi-square tests of independence or Fisher's exact tests for categorical variables when appropriate.\u003c/p\u003e \u003cp\u003eMultivariable linear regression models were used to compare the primary (EHP-30 score for QoL) and secondary outcomes (NRS scores for symptoms of pain) between the endometrioma and non-endometrioma groups. The models were adjusted for age, body mass index, ethnicity, age of menarche, parity, education level, employment status, marital status, annual income, and hormone use in the last three months. Sub-group analyses were performed to determine whether differences in either QoL score or NRS pain scores (when comparing endometrioma group to non-endometrioma group) were associated with potential modification factors. To do so, an interaction term between each factor and variable of interest was added to the models. The factors were the diagnosis method (imaging modalities/histology), concurrent pain symptoms (1\u0026ndash;4/5\u0026ndash;6), comorbid infertility (yes/no), presence of adenomyosis (yes/no), presence of fibroma (yes/no), moderate symptoms of depression (yes/no), moderate symptoms of anxiety (yes/no), pain catastrophizing (yes/no) and central component of pain (yes/no). To aid in clinical interpretation, analyses with cutoffs were conducted using multivariable logistic regression models. The EHP-30 score was categorized as impaired (score\u0026thinsp;\u0026ge;\u0026thinsp;75th centile of EHP-30 score population distribution) or best (score\u0026thinsp;\u0026lt;\u0026thinsp;75th centile of EHP-30 score population distribution) quality of life. The pain NRS scores were categorized as severe (7\u0026ndash;10) or mild-moderate (1\u0026ndash;6) intensity.\u003c/p\u003e \u003cp\u003eWe estimated the point estimates, i.e., linear regression coefficients (β) as mean differences for either QoL or pain symptoms scores, and odds ratios (OR) as ratios of the odds of probability for having either impaired QoL or each severe pain symptom. The estimates were supplemented by their confidence intervals (CI) of 95%. Statistical significance was established for values of p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 for all analyses. A p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 for the interaction term in sub-group analyses indicated that there was a statistically significant difference in effect of the variable of interest on the outcome regarding the whole factor. No sample size calculation was conducted. Participants were included over a complete period to obtain a representative sample of patients with frequent hospital visits. We therefore performed a \u003cem\u003epost hoc\u003c/em\u003e power calculation to assess the statistical power of our main analyses [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. This allowed us to determine that the study was adequately powered to detect minimal clinical differences relevant to patients or healthcare providers [\u003cspan additionalcitationids=\"CR10\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec7\"\u003e\n \u003ch2\u003eCharacteristics of the study population and outcomes distributions\u003c/h2\u003e\n \u003cp\u003eOut of the 335 individuals who were screened, a total of 248 participants (74%) met the criteria for inclusion in our study and were divided into the endometrioma group (81/248; 33%) and non-endometrioma group (167/248; 67%) (Fig.\u0026nbsp;\u003cspan\u003e1\u003c/span\u003e). The mean age of the patients was 37.1\u0026thinsp;\u0026plusmn;\u0026thinsp;7.5 years old, with an average body mass index of 26.6\u0026thinsp;\u0026plusmn;\u0026thinsp;5.7 Kg/m\u003csup\u003e2\u003c/sup\u003e. Most participants were Canadian or North American, accounting for 84% of the sample population. A large proportion of the participants (78%) had their first menstrual period at or before the age of 13, while more than half (54%) was nulliparous. One-third of the patients reported experiencing up to four pain symptoms simultaneously (34%). The non-endometrioma group showed a longer duration of pain symptoms (p\u0026thinsp;=\u0026thinsp;0.047), lower prevalence of presentation of up to four concurrent pain symptoms (p\u0026thinsp;=\u0026thinsp;0.031) and higher prevalence of adenomyosis (p\u0026thinsp;=\u0026thinsp;0.02). No statistically significant difference between endometrioma and non-endometrioma patients emerged across other variables (Table\u0026nbsp;\u003cspan\u003e1\u003c/span\u003e). On average, the QoL score was 45.9\u0026thinsp;\u0026plusmn;\u0026thinsp;25.9. The most reported pain symptoms included deep dyspareunia (90%), chronic pelvic pain (84%) and lower back pain (81%). In cases of severe symptoms (pain intensity of 7 or above), the most common symptoms reported were dysmenorrhea (66%), deep dyspareunia (58%), and chronic pelvic pain (50%) (Table\u0026nbsp;\u003cspan\u003e2\u003c/span\u003e).\u003c/p\u003e\n \u003cdiv\u003e\n \u003ctable id=\"Tab1\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 1\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003eMain characteristics of the study population\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003ccolgroup cols=\"5\"\u003e\u003c/colgroup\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\" rowspan=\"2\"\u003e\n \u003cp\u003eVariables\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eEndometriosis\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" rowspan=\"2\"\u003e\n \u003cp\u003eTotal\u003c/p\u003e\n \u003cp\u003e(N\u0026thinsp;=\u0026thinsp;248)\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" rowspan=\"2\"\u003e\n \u003cp\u003ep-value\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eEndometrioma\u003c/p\u003e\n \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;81)\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eNon endometrioma\u003c/p\u003e\n \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;167)\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e37.0\u0026thinsp;\u0026plusmn;\u0026thinsp;7.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e37.1\u0026thinsp;\u0026plusmn;\u0026thinsp;7.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e37.1\u0026thinsp;\u0026plusmn;\u0026thinsp;7.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.86\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eBody mass index (Kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e26.4\u0026thinsp;\u0026plusmn;\u0026thinsp;5.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e26.7\u0026thinsp;\u0026plusmn;\u0026thinsp;5.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e26.6\u0026thinsp;\u0026plusmn;\u0026thinsp;5.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.83\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCanadian or North American\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e69 (85.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e139 (83.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e208 (83.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.70\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eUniversity level\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e40 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e62 (37.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e102 (41.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.15\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eWorking currently\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e71 (87.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e133 (79.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e204 (82.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIn a relationship/married/spouse\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e66 (81.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e143 (85.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e209 (84.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.40\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eMenarche\u0026thinsp;\u0026le;\u0026thinsp;13 years old\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e60 (74.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e133 (79.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e193 (77.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNulliparous\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e46 (56.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e88 (52.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e134 (54.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.54\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eYears since onset of pain symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9 (3\u0026ndash;18)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12 (5\u0026ndash;22)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11 (5\u0026ndash;20)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.047\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSmoking\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5 (17.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e15 (29.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20 (25.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.26\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHormonal suppression in the last 3 months\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e41 (64.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e90 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e131 (61.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.58\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eComorbid infertility\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e13 (16.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20 (12.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.38\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eReporting 1\u0026ndash;4 concurrent pain symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e31 (44.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e40 (29.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e71 (34.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.031\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAdenomyosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2 (4.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12 (21.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e14 (14.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.020\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eFibroma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12 (57.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e38 (79.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e50 (72.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.060\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePain catastrophizing (PCS\u0026thinsp;\u0026ge;\u0026thinsp;27)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e19 (23.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e48 (28.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e67 (27.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.38\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eModerate anxiety (GAD-7\u0026thinsp;\u0026ge;\u0026thinsp;10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6 (23.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e14 (23.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20 (23.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eModerate depression (PHQ-9\u0026thinsp;\u0026ge;\u0026thinsp;10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9 (34.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e21 (34.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e30 (34.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCentral component of pain (CSI\u0026thinsp;\u0026ge;\u0026thinsp;40)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5 (11.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e15 (17.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20 (15.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.31\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"5\"\u003e\n \u003cp\u003eAbbreviations: PCS, Pain Catastrophizing Scale; GAD-7, Generalized Anxiety Disorder; PHQ-9, Patient Health Questionnaire-9; CSI, Central Sensitization Inventory.\u003c/p\u003e\n \u003cp\u003e\u003csup\u003e1\u003c/sup\u003e Values are given in mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation, median (interquartile range), and frequency (percentage).\u003c/p\u003e\n \u003cp\u003e\u003csup\u003e2\u003c/sup\u003e Wilcoxon rank sum test for continuous variables; and Pearson\u0026rsquo;s Chi-squared test or Fisher\u0026rsquo;s exact test otherwise.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003c/div\u003e\n \u003cdiv\u003e\n \u003ctable id=\"Tab2\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 2\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003eDistribution of the outcomes\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003ccolgroup cols=\"4\"\u003e\u003c/colgroup\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\" rowspan=\"2\"\u003e\n \u003cp\u003eVariables\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eEndometriosis\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" rowspan=\"2\"\u003e\n \u003cp\u003eTotal\u003c/p\u003e\n \u003cp\u003e(N\u0026thinsp;=\u0026thinsp;248)\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eEndometrioma\u003c/p\u003e\n \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;81)\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eNon endometrioma\u003c/p\u003e\n \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;167)\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eQuality of life\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eEHP-30 score\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e42.4\u0026thinsp;\u0026plusmn;\u0026thinsp;25.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e47.6\u0026thinsp;\u0026plusmn;\u0026thinsp;26.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e45.9\u0026thinsp;\u0026plusmn;\u0026thinsp;25.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eImpaired (EHP-30 score\u0026thinsp;\u0026ge;\u0026thinsp;66)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e21 (25.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e48 (28.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e69 (27.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNot available\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSuperficial dyspareunia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHave reported\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e37 (49.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e98 (64.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e135 (59.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIntensity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5.0\u0026thinsp;\u0026plusmn;\u0026thinsp;2.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.1\u0026thinsp;\u0026plusmn;\u0026thinsp;2.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.3\u0026thinsp;\u0026plusmn;\u0026thinsp;2.6\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSevere (intensity\u0026thinsp;\u0026ge;\u0026thinsp;7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e10 (27.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20 (20.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e30 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNot available\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eDeep dyspareunia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHave reported\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e68 (89.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e138 (90.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e206 (90.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIntensity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.0\u0026thinsp;\u0026plusmn;\u0026thinsp;2.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.7\u0026thinsp;\u0026plusmn;\u0026thinsp;2.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.5\u0026thinsp;\u0026plusmn;\u0026thinsp;2.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSevere (intensity\u0026thinsp;\u0026ge;\u0026thinsp;7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e35 (51.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e85 (61.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e120 (58.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNot available\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eDysmenorrhea\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHave reported\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e57 (75.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e124 (81.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e181 (79.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIntensity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.6\u0026thinsp;\u0026plusmn;\u0026thinsp;2.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7.4\u0026thinsp;\u0026plusmn;\u0026thinsp;2.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7.1\u0026thinsp;\u0026plusmn;\u0026thinsp;2.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSevere (intensity\u0026thinsp;\u0026ge;\u0026thinsp;7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e36 (63.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e83 (66.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e119 (65.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNot available\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eDyschezia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHave reported\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e50 (61.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e135 (81.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e185 (75.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIntensity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.9\u0026thinsp;\u0026plusmn;\u0026thinsp;2.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5.0\u0026thinsp;\u0026plusmn;\u0026thinsp;2.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5.0\u0026thinsp;\u0026plusmn;\u0026thinsp;2.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSevere (intensity\u0026thinsp;\u0026ge;\u0026thinsp;7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e14 (28.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e39 (28.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e53 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNot available\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eLower back pain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHave reported\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e64 (79.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e137 (82.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e201 (81.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIntensity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e5.6\u0026thinsp;\u0026plusmn;\u0026thinsp;2.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.4\u0026thinsp;\u0026plusmn;\u0026thinsp;2.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.1\u0026thinsp;\u0026plusmn;\u0026thinsp;2.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSevere (intensity\u0026thinsp;\u0026ge;\u0026thinsp;7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e24 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e65 (47.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e89 (44.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNot available\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChronic pelvic pain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHave reported\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e64 (79.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e143 (85.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e207 (83.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIntensity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.3\u0026thinsp;\u0026plusmn;\u0026thinsp;2.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.6\u0026thinsp;\u0026plusmn;\u0026thinsp;2.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6.5\u0026thinsp;\u0026plusmn;\u0026thinsp;2.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSevere (intensity\u0026thinsp;\u0026ge;\u0026thinsp;7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e27 (42.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e76 (53.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e103 (49.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNot available\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\"\u003eAbbreviation: EHP-30, Endometriosis Health Profile-30.\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\"\u003e\u003csup\u003e\u003cem\u003e1\u003c/em\u003e\u003c/sup\u003e Pain intensity is the numerical rating scale score ranging from 0 (indicating no pain) to 10 (indicating worst pain imaginable); the EHP-30 score ranges from 0 (indicating optimal quality of life) to 100 (indicating worst quality of life); each \u0026ldquo;Not available\u0026rdquo; row displays the number of missing values; each \u0026ldquo;Have reported\u0026rdquo; row denotes the number of cases that reported the corresponding symptom of pain.\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\"\u003e\u003csup\u003e2\u003c/sup\u003e Values are given in mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation and frequency (percentage).\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n \u003c/table\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec8\"\u003e\n \u003ch2\u003eAssociation between QoL and endometriomas\u003c/h2\u003e\n \u003cp\u003eThe unadjusted and adjusted analyses for QoL scores indicated no difference between patients with and without endometriomas (mean difference of -4.9 (95%CI, [-12.7 to 2.9]; p\u0026thinsp;=\u0026thinsp;0.214) and \u0026minus;\u0026thinsp;2.9 (95%CI, [-10.5 to 4.8]; p\u0026thinsp;=\u0026thinsp;0.458) respectively) (Fig.\u0026nbsp;\u003cspan\u003e2\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eNo statistically significant difference in QoL score between participants with endometriomas and those without emerged across the modifying factors. When considering only participants reporting moderate symptoms of depression, there was significantly lower mean QoL score at 29.3 (95%CI, [3.9 to 54.8]) for patients with endometriomas compared to those without (Fig.\u0026nbsp;\u003cspan\u003e3\u003c/span\u003e).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec9\"\u003e\n \u003ch2\u003eAssociation between pain scores and endometriomas\u003c/h2\u003e\n \u003cp\u003eParticipants with endometriomas versus those without endometriomas exhibited significantly higher mean scores for superficial dyspareunia of 1.4 (95%CI, [0.2 to 2.6]; p\u0026thinsp;=\u0026thinsp;0.028), and significantly lower mean scores for deep dyspareunia of 0.8 (95%CI, [0 to 1.5]; p\u0026thinsp;=\u0026thinsp;0.049) in adjusted analyses. For other pain symptoms (dysmenorrhea, dyschezia, lower back pain, chronic pelvic pain), there was no statistically significant differences in mean differences (Fig.\u0026nbsp;\u003cspan\u003e2\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eComorbid infertility (p\u0026thinsp;=\u0026thinsp;0.049) was found to be a factor that influenced the results for superficial dyspareunia, with an average difference in scores of 4.6 (95%CI, [1.2 to 8.1]) if infertility vs 0.9 (95%CI, [-0.3 to 2.2]) otherwise (Figure S2). The central component of pain (p\u0026thinsp;=\u0026thinsp;0.041) emerged as a factor that modified the potential average difference in scores for chronic pelvic pain (2.54; 95%CI, [-0.4 to 5.5] if central component of pain vs -0.7; 95%CI, [-1.8 to 0.3] otherwise (Figure S3).\u003c/p\u003e\n \u003cp\u003eConsidering solely the levels of modifying factors, statistically significant mean score differences were found between participants with endometriomas and those without (i.e., 95% confidence intervals did not include zero). These differences were observed in individuals reporting up to four concurrent symptoms of pain, comorbid infertility, moderate symptoms of anxiety and pain catastrophizing for superficial dyspareunia (Figure S2), absence of a central component in pain experience and no pain catastrophizing for deep dyspareunia (Figure S4), and presence of a central component in pain experience and no pain catastrophizing for lower back pain (Figure S5). No such differences were identified for chronic pelvic pain (Figure S3), dysmenorrhea (Figure S6), dyschezia (Figure S7).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec10\"\u003e\n \u003ch2\u003eOdd radios of impaired QoL and severe pain symptoms\u003c/h2\u003e\n \u003cp\u003eThe OR for impaired QoL (endometrioma vs non-endometrioma) was 1.05 (95%CI, [0.5 to 2.19]; p\u0026thinsp;=\u0026thinsp;0.89). For symptoms of pain, the OR ranged from 0.52 (95%CI, [0.25 to 1.08]; p\u0026thinsp;=\u0026thinsp;0.08) for severe deep dyspareunia to 2.11 (95%CI, [0.60 to 7.43]; p\u0026thinsp;=\u0026thinsp;0.24). Endometrioma was not associated with impaired QoL or any severe symptoms of pain, but the confidence intervals in adjusted analyses indicated that the data were compatible with an OR both greater than and less than 1 (Fig.\u0026nbsp;\u003cspan\u003e4\u003c/span\u003e).\u003c/p\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, we found no difference in quality of life between patients with and without endometriomas. In terms of pain scores, there were differences in deep and superficial dyspareunia. The study echoes research aiming to better quantify and compare endometriosis-associated pain experienced by different women or identify different subpopulations of women with endometriosis. Since no current cure exists for endometriosis, this research supports the development of targeted treatments appropriate to a group with similar clinical experience or to a given subpopulation's underlying biological differences [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe study focused on the quality of life of patients with endometriosis who have different types of lesions. It specifically looks at how endometriosis, as a chronic inflammatory illness, affects their quality of life rather than just considering the presence or absence of pain symptoms. Indeed, the study only involved people who had experienced at least one symptom of pain. These findings add to the limited evidence in terms of the variation in pain and quality of life across endometriosis types. The findings echo earlier research indicating that endometriosis, regardless of type, significantly impacts patients\u0026rsquo; quality of life and pain experiences. Patients with endometriosis seem to have an overall impaired quality of life compared to patients from the general population, including daily tasks, marital/sexual relationships, social life, and employment, as well as physical and psychological aspects of life [\u003cspan additionalcitationids=\"CR14 CR15 CR16 CR17 CR18 CR19\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. In contrast to these previous studies, it should be emphasized that we focused on evaluating quality of life specifically about the experience of pain.\u003c/p\u003e \u003cp\u003eWhile patients with endometriomas indicated significantly higher scores for superficial dyspareunia, lower scores were noted for deep dyspareunia. This finding supports that the pain experience in endometriosis may vary by symptom and endometriosis subtype [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e] since pain may also be due to the anatomical distortion that endometriomas create in the pelvis [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Endometriomas often co-occur with deep endometriosis [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. In this study, the endometrioma group included all cases of endometrioma, regardless of other subtypes. Our study highlights the complex impact of endometriosis and co-occurring conditions (like depression) on quality of life, underscoring the importance of personalized care strategies, including medical, psychological, and non-medical interventions such as physical therapy and lifestyle changes. It also emphasizes the need for the development of targeted medical and surgical treatments to improve patient outcomes. Variations in the perception, nature, and intensity of pain among individuals can account for the differences observed in the results. Additionally, there may be associations between different pain symptoms that contribute to these variations. The finding that associated conditions such as depression could significantly affect quality of life in endometrioma patients compared to non-endometrioma suggests that healthcare providers should consider diagnostic strategies to identify such conditions and involve them in the overall management approach. Other studies will be required to understand which factors explained differences in quality of life among patients with endometriosis.\u003c/p\u003e \u003cp\u003eStrengths of this study included a substantial sample size for main analyses (with sufficient power to detect clinically relevant mean difference), the use of a validated measure for quality of life in the endometriosis population (EHP-30) and the use of appropriate and validated statistical methods to analyze the data. We considered a wide range of modifying factors (such as adenomyosis, comorbid infertility, and psychological factors), which provides a more comprehensive view of factors influencing quality of life and pain in endometriosis patients. The focus on comparing quality of life and pain experiences between endometrioma and other types of endometriosis (comparisons among patients with endometriosis) is a distinct feature of this study, which contributes unique findings to the research field. However, the study was limited by its cross-sectional design, which prevents the ability to establish cause-effect relationships between different types of endometrioses and quality of life or pain experiences. The participants were recruited from a specific clinical setting, which might limit the representativeness of the findings to all patients with endometriosis.\u003c/p\u003e \u003cp\u003eFuture research could benefit from a longitudinal design to determine changes in quality of life and pain scores over time, helping to explore in more depth the relationships between different types of endometrioses, quality of life, specific pain experiences, and other influencing factors. This could lead to more effective approaches to improve the quality of life of endometriosis patients. Further exploration of personalized treatment plans based on the type of endometriosis and the patient's symptoms and assessments of quality of life could be valuable.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eAmong patients with endometriosis, the presence of endometriomas was not associated with a greater or lesser quality of life but difference in specific symptoms of dyspareunia. Further studies will be required to understand which factors explained differences in quality of life among patients with endometriosis.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eCI: Confidence interval\u003c/p\u003e\n\u003cp\u003eEHP-30: Endometriosis Health Profile-30\u003c/p\u003e\n\u003cp\u003eNRS: numerical rating scale\u003c/p\u003e\n\u003cp\u003eOR: odds ratios\u003c/p\u003e\n\u003cp\u003eQoL: quality of life\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eEthics approval and consent to participate\u003c/h2\u003e\n\u003cp\u003eEthical approval (#2020-4972) was obtained from the research ethics committee of \u003cem\u003eCentre Hospitalier Universitaire de Qu\u0026eacute;bec-Universit\u0026eacute; Laval.\u003c/em\u003e Written informed consent was obtained from each participant before participating in the study.\u003c/p\u003e\n\u003ch2\u003eConsent for publication\u003c/h2\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003ch2\u003eAvailability of data and materials\u003c/h2\u003e\n\u003cp\u003eThe datasets generated and/or analyzed during the current study are not publicly available due to privacy/ethical restrictions but are available from the corresponding author (FSK) on reasonable request and with permission of SML.\u003c/p\u003e\n\u003ch2\u003eCompeting interests\u003c/h2\u003e\n\u003cp\u003eThe authors declare that they have no conflicts of interest and nothing to disclose.\u003c/p\u003e\n\u003ch2\u003eFunding\u003c/h2\u003e\n\u003cp\u003eThis research project was funded by the Canadian Institutes of Health Research. S.M.-L. is the recipient of a Career Award from the Fonds de Recherche Qu\u0026eacute;bec-Sant\u0026eacute;. The sponsors had no role in the study design; collection, analysis, and interpretation of data; writing of the report; or the decision to submit the report for publication.\u003c/p\u003e\n\u003ch2\u003eAuthors\u0026apos; contributions\u003c/h2\u003e\n\u003cp\u003eStudy Conception and Design: FSK, VA, SML\u003c/p\u003e\n\u003cp\u003eData Collection: FSK, VA, SML\u003c/p\u003e\n\u003cp\u003eStatistical Analysis: FSK\u003c/p\u003e\n\u003cp\u003eData Analysis and Interpretation of Results: FSK, VA, SML\u003c/p\u003e\n\u003cp\u003eWriting - Original Draft: FSK\u003c/p\u003e\n\u003cp\u003eWriting - Review and Editing: FSK, VA, SML\u003c/p\u003e\n\u003cp\u003eSupervision: SML\u003c/p\u003e\n\u003ch2\u003eAcknowledgements\u003c/h2\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003ch2\u003eAuthors\u0026apos; information\u003c/h2\u003e\n\u003cp\u003eFSK, MD, MPH: Doctoral student in epidemiology (Reproduction, mother and youth health).\u003c/p\u003e\n\u003cp\u003eVA, MSc: Nurse clinician and research professional (Reproduction, mother and youth health).\u003c/p\u003e\n\u003cp\u003eSML, MD, PhD: Gynecologist, clinician-researcher and assistant professor (Reproduction, mother and youth health).\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eC. Allaire, M. A. Bedaiwy, and P. J. Yong, \u0026ldquo;Diagnosis and management of endometriosis,\u0026rdquo; \u003cem\u003eCMAJ\u003c/em\u003e, vol. 195, no. 10, pp. E363\u0026ndash;E371, Mar. 2023, doi: 10.1503/cmaj.220637.\u003c/li\u003e\n\u003cli\u003eN. Rahmioglu \u003cem\u003eet al.\u003c/em\u003e, \u0026ldquo;The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions,\u0026rdquo; \u003cem\u003eNat. Genet.\u003c/em\u003e, vol. 55, no. 3, Art. no. 3, Mar. 2023, doi: 10.1038/s41588-023-01323-z.\u003c/li\u003e\n\u003cli\u003eC. M. Becker \u003cem\u003eet al.\u003c/em\u003e, \u0026ldquo;ESHRE guideline: endometriosis,\u0026rdquo; \u003cem\u003eHum. Reprod. Open\u003c/em\u003e, vol. 2022, no. 2, p. hoac009, Feb. 2022, doi: 10.1093/hropen/hoac009.\u003c/li\u003e\n\u003cli\u003eG. Jones, S. Kennedy, A. Barnard, J. Wong, and C. Jenkinson, \u0026ldquo;Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30,\u0026rdquo; \u003cem\u003eObstet. Gynecol.\u003c/em\u003e, vol. 98, no. 2, pp. 258\u0026ndash;264, Aug. 2001, doi: 10.1016/S0029-7844(01)01433-8.\u003c/li\u003e\n\u003cli\u003eE. Dimentberg, C. Cardaillac, E. Richard, A.-S. Plante, and S. Maheux-Lacroix, \u0026ldquo;Translation and Cultural Validation of the WERF EPHect Endometriosis Patient Questionnaire into Canadian French,\u0026rdquo; \u003cem\u003eJ. Obstet. Gynaecol. Can. JOGC J. Obstet. Gynecol. Can. JOGC\u003c/em\u003e, vol. 43, no. 7, pp. 817\u0026ndash;821, Jul. 2021, doi: 10.1016/j.jogc.2021.03.019.\u003c/li\u003e\n\u003cli\u003eK. Vincent, S. Kennedy, and P. Stratton, \u0026ldquo;Pain scoring in endometriosis: entry criteria and outcome measures for clinical trials. Report from the Art and Science of Endometriosis meeting,\u0026rdquo; \u003cem\u003eFertil. Steril.\u003c/em\u003e, vol. 93, no. 1, pp. 62\u0026ndash;67, Jan. 2010, doi: 10.1016/j.fertnstert.2008.09.056.\u003c/li\u003e\n\u003cli\u003eR Core Team, \u0026ldquo;R: A language and environment for statistical computing.\u0026rdquo; R Foundation for Statistical Computing, Vienna, Austria, 2023. [Online]. Available: https://www.R-project.org/\u003c/li\u003e\n\u003cli\u003eJ. A. Hanley and E. E. M. Moodie, \u0026ldquo;Sample Size, Precision and Power Calculations: A Unified Approach,\u0026rdquo; \u003cem\u003eJ. Biom. Biostat.\u003c/em\u003e, vol. 2, no. 124, pp. 1\u0026ndash;9, 2011, doi: http://dx.doi.org/10.4172/2155-6180.1000124.\u003c/li\u003e\n\u003cli\u003eT. J. M. van de Burgt, K. B. Kluivers, and J. C. M. Hendriks, \u0026ldquo;Responsiveness of the Dutch Endometriosis Health Profile-30 (EHP-30) questionnaire,\u0026rdquo; \u003cem\u003eEur. J. Obstet. Gynecol. Reprod. Biol.\u003c/em\u003e, vol. 168, no. 1, pp. 92\u0026ndash;94, May 2013, doi: 10.1016/j.ejogrb.2012.12.037.\u003c/li\u003e\n\u003cli\u003eR. Pokrzywinski, A. M. Soliman, J. Chen, M. C. Snabes, H. S. Taylor, and K. S. Coyne, \u0026ldquo;Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials,\u0026rdquo; \u003cem\u003eJ. Womens Health\u003c/em\u003e, vol. 29, no. 2, pp. 253\u0026ndash;261, Feb. 2020, doi: 10.1089/jwh.2019.7788.\u003c/li\u003e\n\u003cli\u003eR. M. Pokrzywinski, A. M. Soliman, M. C. Snabes, J. Chen, H. S. Taylor, and K. S. Coyne, \u0026ldquo;Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis,\u0026rdquo; \u003cem\u003eFertil. Steril.\u003c/em\u003e, vol. 115, no. 2, pp. 423\u0026ndash;430, Feb. 2021, doi: 10.1016/j.fertnstert.2020.07.013.\u003c/li\u003e\n\u003cli\u003eA. Muraoka \u003cem\u003eet al.\u003c/em\u003e, \u0026ldquo;Fusobacterium infection facilitates the development of endometriosis through the phenotypic transition of endometrial fibroblasts,\u0026rdquo; \u003cem\u003eSci. Transl. Med.\u003c/em\u003e, vol. 15, no. 700, p. eadd1531, Jun. 2023, doi: 10.1126/scitranslmed.add1531.\u003c/li\u003e\n\u003cli\u003eG. Jones, C. Jenkinson, and S. Kennedy, \u0026ldquo;The impact of endometriosis upon quality of life: a qualitative analysis,\u0026rdquo; \u003cem\u003eJ. Psychosom. Obstet. Gynecol.\u003c/em\u003e, vol. 25, no. 2, pp. 123\u0026ndash;133, Jan. 2004, doi: 10.1080/01674820400002279.\u003c/li\u003e\n\u003cli\u003eK. E. Nnoaham \u003cem\u003eet al.\u003c/em\u003e, \u0026ldquo;Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries,\u0026rdquo; \u003cem\u003eFertil. Steril.\u003c/em\u003e, vol. 96, no. 2, pp. 366-373.e8, Aug. 2011, doi: 10.1016/j.fertnstert.2011.05.090.\u003c/li\u003e\n\u003cli\u003eM. Moradi, M. Parker, A. Sneddon, V. Lopez, and D. Ellwood, \u0026ldquo;Impact of endometriosis on women\u0026rsquo;s lives: a qualitative study,\u0026rdquo; \u003cem\u003eBMC Womens Health\u003c/em\u003e, vol. 14, no. 1, p. 123, Oct. 2014, doi: 10.1186/1472-6874-14-123.\u003c/li\u003e\n\u003cli\u003eK. Chaman-Ara, M. A. Bahrami, M. Moosazadeh, and E. Bahrami, \u0026ldquo;Quality of life in women with endometriosis: a systematic review and meta-analysis,\u0026rdquo; \u003cem\u003eWorld Cancer Res. J. Accept. Artic.\u003c/em\u003e, 2017.\u003c/li\u003e\n\u003cli\u003eA. M. Soliman, K. S. Coyne, K. S. Gries, J. Castelli-Haley, M. C. Snabes, and E. S. Surrey, \u0026ldquo;The Effect of Endometriosis Symptoms on Absenteeism and Presenteeism in the Workplace and at Home,\u0026rdquo; \u003cem\u003eJ. Manag. Care Spec. Pharm.\u003c/em\u003e, vol. 23, no. 7, pp. 745\u0026ndash;754, Jul. 2017, doi: 10.18553/jmcp.2017.23.7.745.\u003c/li\u003e\n\u003cli\u003eL. Della Corte \u003cem\u003eet al.\u003c/em\u003e, \u0026ldquo;The Burden of Endometriosis on Women\u0026rsquo;s Lifespan: A Narrative Overview on Quality of Life and Psychosocial Wellbeing,\u0026rdquo; \u003cem\u003eInt. J. Environ. Res. Public. Health\u003c/em\u003e, vol. 17, no. 13, p. 4683, Jul. 2020, doi: 10.3390/ijerph17134683.\u003c/li\u003e\n\u003cli\u003eD. Warzecha, I. Szymusik, M. Wielgos, and B. Pietrzak, \u0026ldquo;The Impact of Endometriosis on the Quality of Life and the Incidence of Depression\u0026mdash;A Cohort Study,\u0026rdquo; \u003cem\u003eInt. J. Environ. Res. Public. Health\u003c/em\u003e, vol. 17, no. 10, p. 3641, May 2020, doi: 10.3390/ijerph17103641.\u003c/li\u003e\n\u003cli\u003eM. Kalfas, C. Chisari, and S. Windgassen, \u0026ldquo;Psychosocial factors associated with pain and health‐related quality of life in Endometriosis: A systematic review,\u0026rdquo; \u003cem\u003eEur. J. Pain Lond. Engl.\u003c/em\u003e, vol. 26, no. 9, pp. 1827\u0026ndash;1848, Oct. 2022, doi: 10.1002/ejp.2006.\u003c/li\u003e\n\u003cli\u003eF. Facchin \u003cem\u003eet al.\u003c/em\u003e, \u0026ldquo;Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference,\u0026rdquo; \u003cem\u003eJ. Psychosom. Obstet. Gynecol.\u003c/em\u003e, vol. 36, no. 4, pp. 135\u0026ndash;141, Oct. 2015, doi: 10.3109/0167482X.2015.1074173.\u003c/li\u003e\n\u003cli\u003eA. V. de A. Florentino, A. M. G. Pereira, J. A. Martins, R. G. C. Lopes, and R. M. Arruda, \u0026ldquo;Quality of Life Assessment by the Endometriosis Health Profile (EHP-30) Questionnaire Prior to Treatment for Ovarian Endometriosis in Brazilian Women,\u0026rdquo; \u003cem\u003eRev. Bras. Ginecol. E Obstetr\u0026iacute;cia RBGO Gynecol. Obstet.\u003c/em\u003e, vol. 41, no. 09, pp. 548\u0026ndash;554, Sep. 2019, doi: 10.1055/s-0039-1693057.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-womens-health","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bmwh","sideBox":"Learn more about [BMC Women's Health](http://bmcwomenshealth.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bmwh/default.aspx","title":"BMC Women's Health","twitterHandle":"","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Endometriosis, endometrioma, quality of life, Endometriosis Health Profile-30, pelvic pain, infertility","lastPublishedDoi":"10.21203/rs.3.rs-3734629/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3734629/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eEndometriomas are genetically distinct from other endometriosis lesions and could be associated with a predisposition to excessive inflammation. However, differences in clinical presentation between types of endometriosis lesions remain understudied. This study aimed to investigate the quality of life and pain scores among patients with endometrioma compared to those with other types of endometriosis lesions.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eA cross-sectional observational study was conducted between January 2020 and August 2023. Patients diagnosed with endometriosis completed the Endometriosis Health Profile 30 pain subscale questionnaire for their quality of life score and rated their endometriosis-associated pain symptoms using an 11-point numerical rating scale. Data were analyzed for comparison through multivariable linear regression models.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eA total of 248 patients were included and divided into endometrioma (81, 33%) and non-endometrioma (167, 67%) groups. The mean age of the patients was 37.1\u0026thinsp;\u0026plusmn;\u0026thinsp;7.5 years old. Most participants were Canadian or North American (84%). One-third of the patients reported experiencing up to four concurrent pain symptoms. The most reported pain included deep dyspareunia (90%), chronic pelvic pain (84%) and lower back pain (81%). The mean quality of life score was 45.9\u0026thinsp;\u0026plusmn;\u0026thinsp;25.9. We observed no difference in quality of life score between patients with and without endometriomas. Patients with endometriomas had lower mean scores for deep dyspareunia of 0.8 (95%CI, [0 to 1.5]; p\u0026thinsp;=\u0026thinsp;0.049) and higher for superficial dyspareunia of 1.4 (95%CI, [0.2 to 2.6]; p\u0026thinsp;=\u0026thinsp;0.028).\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eAmong patients with endometriosis, the presence of endometriomas is not associated with a greater or lesser quality of life but difference in specific symptoms of dyspareunia.\u003c/p\u003e","manuscriptTitle":"Quality of life and symptoms of pain in patients with endometriomas compared to those with other endometriosis lesions: a cross-sectional study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-12-13 20:12:21","doi":"10.21203/rs.3.rs-3734629/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2023-12-20T11:47:26+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2023-12-19T13:46:19+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"3c4070ee-703f-4931-9c3f-51fc94e92ccd_SNPRID","date":"2023-12-18T21:41:55+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2023-12-18T17:41:26+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"e99079b1-573d-4696-bb99-8d7acf632fa7","date":"2023-12-13T19:53:59+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2023-12-12T14:34:52+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"b3acea72-ba8c-49c0-b2f8-a4e7696dac88","date":"2023-12-11T12:03:47+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"10ecc9e9-bb0c-44b4-82f1-e470be2a43e5","date":"2023-12-11T11:57:29+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2023-12-11T11:54:50+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2023-12-11T11:53:01+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2023-12-10T18:36:13+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2023-12-10T18:34:13+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Women's Health","date":"2023-12-10T15:04:28+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-womens-health","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bmwh","sideBox":"Learn more about [BMC Women's Health](http://bmcwomenshealth.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bmwh/default.aspx","title":"BMC Women's Health","twitterHandle":"","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"69e1133a-ac0f-4d9a-a3e8-2a325cedf984","owner":[],"postedDate":"December 13th, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-01-29T15:28:41+00:00","versionOfRecord":{"articleIdentity":"rs-3734629","link":"https://doi.org/10.1186/s12905-024-02919-1","journal":{"identity":"bmc-womens-health","isVorOnly":false,"title":"BMC Women's Health"},"publishedOn":"2024-01-27 15:18:40","publishedOnDateReadable":"January 27th, 2024"},"versionCreatedAt":"2023-12-13 20:12:21","video":"","vorDoi":"10.1186/s12905-024-02919-1","vorDoiUrl":"https://doi.org/10.1186/s12905-024-02919-1","workflowStages":[]},"version":"v1","identity":"rs-3734629","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3734629","identity":"rs-3734629","version":["v1"]},"buildId":"WvIrzKhiLBfengagbw6Ux","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}